Live feed07:30:00·2030dPRReleasevia QuantisnowAeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of HomocystinuriaByQuantisnow·Wall Street's wire, on your screen.AGLE· Aeglea BioTherapeutics Inc.Health CareOriginal source
